GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved for diabetes and weight loss, but growing evidence suggests their effects may extend beyond blood sugar and body fat, according to a March 27 analysis by The Washington Post.
Researchers have identified 13 areas where GLP-1 drugs show proven, promising or theoretical benefits — including kidney and liver disease, cardiovascular health, sleep apnea, arthritis, substance use and even Alzheimer’s disease. Most benefits are supported by early-stage data, but others, such as heart and kidney protection, are backed by large clinical trials.
Here’s the full list of potential health benefits:
- Kidney disease: A large clinical trial found semaglutide significantly reduced kidney complications in patients with Type 2 diabetes and chronic kidney disease.
- Heart disease: FDA-approved to reduce cardiovascular events in patients with obesity; shown to lower risk of heart attack and stroke.
- Liver disease: Semaglutide improved outcomes for metabolic dysfunction-associated steatohepatitis and liver fibrosis.
- Sleep apnea: Tirzepatide reduced nighttime breathing interruptions in trials; Zepbound approved for moderate to severe cases.
- Alzheimer’s and dementia: Observational studies show reduced risk, but randomized trials have not confirmed cognitive benefit.
- Addiction: Linked to reduced risk of alcohol, nicotine, cannabis and opioid use disorders in veterans; active trials are underway.
- Arthritis and inflammation: Small studies suggest reduced knee pain and systemic inflammation, though weight loss may be a factor.
- Asthma: A U.K. study found symptom improvement in obese patients with asthma, likely due to reduced inflammation.
- Cancers: Early data shows possible protective effects against obesity-related cancers, though risks (e.g., thyroid) are still being studied.
- COVID-19: Semaglutide use associated with fewer complications and lower mortality after infection in people with obesity.
- Fertility: Some evidence suggests GLP-1s may indirectly support fertility through weight loss; research is ongoing.
- “Food noise:” Clinical trials show reduced cravings and obsessive thoughts about food, likely due to brain reward pathway changes.
- Polycystic ovary syndrome: GLP-1s may regulate menstrual cycles and support weight loss in women with PCOS; multiple trials are in progress.
The range of potential benefits is prompting researchers to reexamine how metabolic, immune and neurological systems are connected — and whether a single class of drugs could address multiple chronic conditions at once.
